Juventas Therapeutics Phase II Clinical Study Results to be Presented at 2014 American Heart Association Scientific Sessions

News release provided by PR Newswire.

Juventas Therapeutics Inc., a privately-held, clinical-stage company developing novel therapies for treatment of cardiovascular disease, today announced that investigators will present results from two independent clinical trials that show JVS-100, a non-viral gene therapy expressing stromal cell-derived factor 1 (SDF-1), improves clinical status of patients with critical limb ischemia (CLI) and symptomatic ischemic heart failure at the American Heart Association Scientific Sessions 2014 on Nov. 17 in Chicago, Ill.

Click here to read the complete article.

Originally published November 12, 2014.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: